Revvity Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Revvity Inc trades at $110.7 (market cap $11.87B), while iShares 0 3 Month Treasury Bond ETF trades at $100.6. The key difference: Revvity Inc pays a 0.26% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | SGOV | |
|---|---|---|
Market Cap | $11.87B | — |
Sector | Technology | Fixed Income |
52-Week High | $117.75 | $100.74 |
52-Week Low | $82.26 | $100.28 |
Enterprise Value | $14.36B | — |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59, up slightly by 0.01% today. Technical indicators show a bullish trend with strong moving average support, though oscillators are neutral. The ETF provides exposure to short-term U.S. Treasury bills, offering liquidity and a low expense ratio of 0.09%. Recent news highlights institutional interest, such as Advisortrust Partners LLC acquiring a $615,000 position.
The outlook for SGOV is stable, benefiting from its role as a cash management tool amid rate uncertainty. Investment appeal lies in its safety and yield relative to cash, but risks include potential Fed rate hikes impacting short-term bond prices. Investors seeking low-risk income may find SGOV attractive, though returns are modest compared to equities.
Trailing returns across standard periods
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →